SGX Stocks and Warrants

Author: kimeng   |   Latest post: Mon, 4 Jan 2021, 3:02 PM


SATS Ltd (SATS SP) - Beneficiary of Vaccine Shipment

Author:   |    Publish date:

SATS’s 2QFY21 revenue fell 53.5% YoY to S$231.1m due to weak aviation revenue, but partially offset by higher non-aviation revenue. S$31.6m of impairment charges were made on investment in an associate and long-term investment due to the pandemic. As such, 2QFY21 PATMI remained in losses at S$33.2m as compared to a profit of S$60.7m in 2QFY20.

The losses, however, were narrowed on a QoQ basis. No interim dividends were declared as compared to 6 S cents in the same quarter last year on cash conservation.

We understand from management that SATS and several of its subsidiaries and associates are CEIV Pharma certified to handle the Pfizer vaccines which requires temperature handling of minus 75-80 degrees Celsius. Management added that SATS handled shipments which required similar temperature before and are confident that they could use their network to handle the shipments of vaccines next year. We believe this would provide significant opportunities for SATS.

After adjustments, our fair value estimate increases from S$2.93 to S$4.31 on better outlook and near-term catalyst from potential vaccine shipments. Upgrade from Hold to BUY.

Source: OCBC Research - 16 Nov 2020

Share this
Labels: SATS

Related Stocks

Chart Stock Name Last Change Volume 
SATS 3.97 -0.02 (0.50%) 2,271 

  Be the first to like this.

I3 Messenger
Individual or Group chat with anyone on I3investor

168  275  188  518 

Top 10 Active Counters
 Oceanus^ 0.047-0.002 
 LionGold 0.005+0.001 
 AusGroup 0.0380.00 
 Jiutian Chemical 0.108-0.001 
 Eucon^ 0.086+0.016 
 MarcoPolo Marine 0.021-0.002 
 MMP Resources^ 0.006+0.002 
 Blumont^ 0.005-0.001 
 Synagie 0.068+0.004 
 ETC Singapore 0.052+0.001